A desirable start to the year
06/05/25 -"Q1 results met expectations, and strong growth was witnessed across the segments as well as three key molecules. Of note was a rebound in the animal healthcare segment, which benefited from the start ..."
Pages
49
Language
English
Published on
06/05/25
You may also be interested by these reports :
07/05/25
Q1 profits exceeded the street’s expectations. Nonetheless, 2025 guidance was downgraded owing to competition from compounded drugs, which, however, ...
06/05/25
1:10 share split adjustments – Downgrade to Add (prev.: Buy)
06/05/25
Q1 results met expectations, and strong growth was witnessed across the segments as well as three key molecules. Of note was a rebound in the animal ...
05/05/25
BioNTech’s narrative is straightforward: the company develops drugs for life-threatening illnesses and generated significant revenue by developing ...